scholarly journals Reprogramming rat embryonic fibroblasts into induced pluripotent stem cells using transposon vectors and their chondrogenic differentiation in vitro

2014 ◽  
Vol 11 (2) ◽  
pp. 989-994 ◽  
Author(s):  
JIAKUAN YE ◽  
JUNYI HONG ◽  
FUSHENG YE
2018 ◽  
Vol 127 ◽  
pp. S1255-S1256
Author(s):  
E. Stelcer ◽  
K. Kulcenty ◽  
M. Ruciński ◽  
K. Jopek ◽  
T. Trzeciak ◽  
...  

Animals ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 425
Author(s):  
Xia Yuan ◽  
Chen Zhang ◽  
Ruifeng Zhao ◽  
Jingyi Jiang ◽  
Xiang Shi ◽  
...  

Somatic cells can be reprogrammed into induced pluripotent stem cells (iPSCs) in vitro. Previously, a lentivirus induction strategy of introducing Oct4, Sox2, Nanog and Lin28 (OSNL) into the iPSC process has been shown as a possible way to produce chicken iPSCs from chicken embryonic fibroblasts, but the induction efficiency of this method was found to be significantly limiting. In order to help resolve this efficiency obstacle, this study seeks to clarify the associated regulation mechanisms and optimizes the reprogramming strategy of chicken iPSCs. This study showed that glycolysis and the expression of glycolysis-related genes correlate with a more efficient reprogramming process. At the same time, the transcription factors Oct4, Sox2 and Nanog were found to activate the expression of glycolysis-related genes. In addition, we introduced two small-molecule inhibitors (2i-SP) as a “glycolysis activator” together with the OSNL cocktail, and found that this significantly improved the induction efficiency of the iPSC process. As such, the study identifies direct molecular connections between core pluripotency factors and glycolysis during the chicken iPSC induction process and, with its results, provides a theoretical basis and technical support for chicken somatic reprogramming.


2012 ◽  
Vol 21 (6) ◽  
pp. 965-976 ◽  
Author(s):  
Leonhard Linta ◽  
Marianne Stockmann ◽  
Karin N. Kleinhans ◽  
Anja Böckers ◽  
Alexander Storch ◽  
...  

2021 ◽  
Vol 22 (9) ◽  
pp. 4334
Author(s):  
Katrina Albert ◽  
Jonna Niskanen ◽  
Sara Kälvälä ◽  
Šárka Lehtonen

Induced pluripotent stem cells (iPSCs) are a self-renewable pool of cells derived from an organism’s somatic cells. These can then be programmed to other cell types, including neurons. Use of iPSCs in research has been two-fold as they have been used for human disease modelling as well as for the possibility to generate new therapies. Particularly in complex human diseases, such as neurodegenerative diseases, iPSCs can give advantages over traditional animal models in that they more accurately represent the human genome. Additionally, patient-derived cells can be modified using gene editing technology and further transplanted to the brain. Glial cells have recently become important avenues of research in the field of neurodegenerative diseases, for example, in Alzheimer’s disease and Parkinson’s disease. This review focuses on using glial cells (astrocytes, microglia, and oligodendrocytes) derived from human iPSCs in order to give a better understanding of how these cells contribute to neurodegenerative disease pathology. Using glia iPSCs in in vitro cell culture, cerebral organoids, and intracranial transplantation may give us future insight into both more accurate models and disease-modifying therapies.


Sign in / Sign up

Export Citation Format

Share Document